Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial
Merck Sharp & Dohme LLC
Chloe Orkin; Rosie Mngqibisa; Juan Diego Velez; Princy Kumar; Dominique L Braun; Andrew Carr; Mark Bloch; Sharon Walmsley; Pablo Tebas; Yoshiyuki Yokomaku; Tracy L Diamond; Beth Jackson; Karen Eves; Anjana Grandhi; Monica Fuszard; Stephanie O Klopfer; Luisa M Stamm; Michelle C Fox; Jason Kim